206 results on '"Ballestri, Stefano"'
Search Results
2. Endpoints in NASH Clinical Trials: Are We Blind in One Eye?
3. Direct Oral Anticoagulants in Patients with Liver Disease in the Era of Non-Alcoholic Fatty Liver Disease Global Epidemic: A Narrative Review
4. Pathogenesis of hypothyroidism-induced NAFLD: Evidence for a distinct disease entity?
5. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
6. The sequential use of liver stiffness measurement and direct biomarkers of fibrosis is able to identify patients with severe non-alcoholic steatohepatitis
7. Ultrasonographic fatty liver indicator detects mild steatosis and correlates with metabolic/histological parameters in various liver diseases
8. A “systems medicine” approach to the study of non-alcoholic fatty liver disease
9. Epidemiological modifiers of non-alcoholic fatty liver disease: Focus on high-risk groups
10. Liver fibrosis in nonalcoholic fatty liver disease patients: noninvasive evaluation and correlation with cardiovascular disease and mortality
11. Nonalcoholic fatty liver disease: A precursor of the metabolic syndrome
12. NAFLD as a Sexual Dimorphic Disease: Role of Gender and Reproductive Status in the Development and Progression of Nonalcoholic Fatty Liver Disease and Inherent Cardiovascular Risk
13. Risk and Management of Bleeding Complications with Direct Oral Anticoagulants in Patients with Atrial Fibrillation and Venous Thromboembolism: a Narrative Review
14. Cardiovascular Disease and Myocardial Abnormalities in Nonalcoholic Fatty Liver Disease
15. The Role of Nuclear Receptors in the Pathophysiology, Natural Course, and Drug Treatment of NAFLD in Humans
16. First Human Case of Tick-Borne Encephalitis in Non-Endemic Region in Italy: A Case Report
17. Primary lymphoma of the spleen mimicking simple benign cysts: contrast-enhanced ultrasonography and other imaging findings
18. Referee report. For: Overuse and underuse of cardiovascular diagnostic and therapeutic procedures for community-dwelling adults: a protocol for a systematic review [version 1; peer review: 1 approved]
19. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
20. Do ultrasonographic semiquantitative indices predict histological changes in NASH irrespective of steatosis extent?
21. Is nonalcoholic steatohepatitis associated with a high-though-normal thyroid stimulating hormone level and lower cholesterol levels?
22. SAT-517 - The sequential use of liver stiffness measurement and direct biomarkers of fibrosis is able to identify patients with severe non-alcoholic steatohepatitis
23. Liver Fibrosis Biomarkers Accurately Exclude Advanced Fibrosis and Are Associated with Higher Cardiovascular Risk Scores in Patients with NAFLD or Viral Chronic Liver Disease
24. Diagnostic accuracy of ultrasonography for the detection of hepatic steatosis: an updated meta-analysis of observational studies
25. The Fatty liver Index (FLI) 15 years later: a reappraisal
26. Sex disparity in hepatocellular carcinoma owing to NAFLD and non-NAFLD etiology: epidemiological findings and pathobiological mechanisms
27. Ultrasonographic fatty liver indicator, a novel score which rules out NASH and is correlated with metabolic parameters in NAFLD
28. Hepatocellular carcinoma in a patient treated with efalizumab for psoriasis
29. Nonalcoholic fatty liver disease activity score and Bruntʼs pathologic criteria for the diagnosis of nonalcoholic steatohepatitis: What do they mean and do they agree?
30. Genetic determinants of susceptibility and severity in nonalcoholic fatty liver disease
31. Semi-Quantitative Ultrasonographic Evaluation of NAFLD
32. Perspectives of nonalcoholic fatty liver disease research: a personal point of view
33. Do diabetes and obesity promote hepatic fibrosis in familial heterozygous hypobetalipoproteinemia?
34. Differential effect of oleic and palmitic acid on lipid accumulation and apoptosis in cultured hepatocytes
35. The neck-liver axis. Madelung disease as further evidence for an impact of body fat distribution on hepatic histology
36. Sex Differences in NAFLD: State of the Art and Identification of Research Gaps
37. Sex Differences in Nonalcoholic Fatty Liver Disease: State of the Art and Identification of Research Gaps
38. Cardiovascular Risk in Non-Alcoholic Fatty Liver Disease: Mechanisms and Therapeutic Implications
39. Extra-Hepatic Manifestations and Complications of Nonalcoholic Fatty Liver Disease
40. A critical appraisal of the use of ultrasound in hepatic steatosis
41. A round trip from nonalcoholic fatty liver disease to diabetes: molecular targets to the rescue?
42. Nonalcoholic fatty liver disease is associated with an almost twofold increased risk of incident type 2 diabetes and metabolic syndrome. Evidence from a systematic review and meta-analysis
43. Do Nonalcoholic Fatty Liver Disease and Fetuin-A Play Different Roles in Symptomatic Coronary Artery Disease and Peripheral Arterial Disease?
44. Clinical relevance of liver histopathology and different histological classifications of NASH in adults
45. NAFLD, Hepatotropic Viruses, and Cardiometabolic Risk
46. “ Not all forms of NAFLD were created equal ”. Do metabolic syndrome-related NAFLD and PNPLA3 -related NAFLD exert a variable impact on the risk of early carotid atherosclerosis?
47. Clinical features and natural history of cryptogenic cirrhosis compared to hepatitis C virus-related cirrhosis
48. A 'systems medicine' approach to the study of non-alcoholic fatty liver disease
49. The independent predictors of non‐alcoholic steatohepatitis and its individual histological features.
50. Type 2 Diabetes in Non-Alcoholic Fatty Liver Disease and Hepatitis C Virus Infection—Liver: The “Musketeer” in the Spotlight
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.